ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : Industry : Millennium Pharmaceuticals


Include trials that are no longer recruiting patients.

19 studies were found.
1.No longer recruitingBortezomib Compared With Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: refractory plasma cell neoplasm
2.RecruitingBortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Condition: recurrent mantle cell lymphoma
3.RecruitingEARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-segment Elevation Acute Coronary Syndrome
Condition: Myocardial Ischemia
4.RecruitingMLN2704 in Subjects with Metastatic Androgen-Independent Prostate Cancer
Condition: Prostatic Neoplasms
5.TerminatedOpen-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE.
Condition: Multiple Myeloma
6.RecruitingPhase 1 Single Ascending Dose Trial of MLN2704 in Subjects with Metastatic Androgen Independent Prostate Cancer
Condition: Prostate Cancer
7.No longer recruitingPhase 2 Study of VELCADE Alone or VELCADE® plus Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Condition: Non-small cell lung cancer
8.RecruitingPhase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
9.RecruitingA Phase 2 Study of VELCADE® (bortezomib) with Rituximab in Subjects with Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: B-Cell Lymphoma; Follicular Lymphoma; Marginal Lymphoma
10.No longer recruitingPhase 2b Study of VELCADE Alone and VELCADE plus Irinotecan in Patients with Relapsed or Refractory Colorectal Carcinoma
Condition: Colorectal Carcinoma
11.TerminatedPhase I Dose Escalation study of VELCADE plus Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Conditions: Advanced Non-Small Cell Lung Cancer; Other Solid Tumors
12.No longer recruitingPhase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Condition: Prostatic Neoplasms
13.No longer recruitingPS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
14.RecruitingPS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
15.RecruitingRepeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
Condition: Multiple Myeloma
16.RecruitingSafety and Tolerance Study of Oral Doses of CT53518 to Treat Patients with Acute Myelogenous Leukemia (AML)
Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
17.RecruitingStudy of Combination PS-341 and Thalidomide in Multiple Myeloma
Condition: Multiple Myeloma
18.RecruitingA Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
Condition: Multiple Myeloma
19.RecruitingUARK 2003-33, Total Therapy III
Condition: Multiple Myeloma

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act